(Q34501177)

2 August 2017

title

Health-care costs of losartan and candesartan in the primary treatment of hypertension (English)

1 reference

2 August 2017

1 reference

4

S Kjeldsen

1 reference

2 August 2017

M Henriksson

1

1 reference

2 August 2017

D Russell

2

1 reference

2 August 2017

J Bodegard

3

1 reference

2 August 2017

P Hasvold

5

1 reference

2 August 2017

J Stålhammar

6

1 reference

2 August 2017

L-Å Levin

7

1 reference

2 August 2017

publication date

8 April 2010

1 reference

Journal of Human Hypertension

2 August 2017

published in

1 reference

2 August 2017

volume

25

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

130-136

1 reference

https://scigraph.springernature.com/pub.10.1038/jhh.2010.36

2 August 2017

exact match

0 references

cites work

Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023072

7 July 2018

Essential hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023072

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023072

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023072

Health economic guidelines--similarities, differences and some implications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023072

How should cost data in pragmatic randomised trials be analysed?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3023072

Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States

7 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FJHH.2010.36

Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FJHH.2010.36

Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FJHH.2010.36

21 January 2018

Identifiers

DOI

10.1038/JHH.2010.36

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference

2 August 2017

1 reference